63 199

Cited 5 times in

Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database

DC Field Value Language
dc.contributor.author김명수-
dc.contributor.author이재근-
dc.date.accessioned2022-09-06T06:41:43Z-
dc.date.available2022-09-06T06:41:43Z-
dc.date.issued2020-02-
dc.identifier.issn1011-8934-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/190268-
dc.description.abstractBackground: Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population. Methods: Korean Organ Transplantation Registry (KOTRY) database and additionally collected data (n = 326) were analyzed with special reference to types of HBV prophylaxis. Results: The study cohort comprised 267 cases of living-donor LT and 59 cases of deceased-donor LT. Hepatocellular carcinoma (HCC) was diagnosed in 232 (71.2%) of these subjects. Antiviral agents were used in 255 patients (78.2%) prior to LT. HBV DNA was undetectable in 69 cases (21.2%) and detectable over wide concentrations in the other 257 patients (78.8%) prior to LT. Polymerase chain reaction analysis of the store blood samples detected HBV DNA in all patients, with 159 patients (48.9%) showing concentrations > 100 IU/mL. Post-transplant HBV regimens during the first year included combination therapy in 196 (60.1%), hepatitis B immunoglobulin (HBIG) monotherapy in 121 (37.1%), and antiviral monotherapy in 9 (2.8%). In the second post-transplant year, these regimens had changed to combination therapy in 187 (57.4%), HBIG monotherapy in 112 (34.4%), and antiviral monotherapy in 27 (8.3%). Trough antibody to hepatitis B surface antigen titers > 500 IU/mL and >1,000 IU/mL were observed in 61.7% and 25.2%, respectively. The mean simulative half-life of HBIG was 21.6 +/- 4.3 days with a median 17.7 days. Up to 2-year follow-up period, HCC recurrence and HBV recurrence developed in 18 (5.5%) and 6 (1.8%), respectively. HCC recurrence developed in 3 of 6 patients with HBV recurrence. Conclusion: Combination therapy is the mainstay of HBV prophylaxis protocols in a majority of Korean LT centers, but HBIG was often administered excessively. Individualized optimization of HBIG treatments using SHL is necessary to adjust the HBIG infusion interval.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisher대한의학회(The Korean Academy of Medical Sciences)-
dc.relation.isPartOfJOURNAL OF KOREAN MEDICAL SCIENCE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntiviral Agents* / therapeutic use-
dc.subject.MESHCohort Studies-
dc.subject.MESHDNA, Viral / blood-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHHepatitis B Surface Antigens / blood-
dc.subject.MESHHepatitis B virus* / genetics-
dc.subject.MESHHepatitis B* / prevention & control-
dc.subject.MESHHumans-
dc.subject.MESHImmunoglobulins* / therapeutic use-
dc.subject.MESHLiver Transplantation*-
dc.subject.MESHLiving Donors*-
dc.subject.MESHRegistries-
dc.subject.MESHRepublic of Korea-
dc.titleHepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorGil Chun Park-
dc.contributor.googleauthorShin Hwang-
dc.contributor.googleauthorMyoung Soo Kim-
dc.contributor.googleauthorDong Hwan Jung-
dc.contributor.googleauthorGi Won Song-
dc.contributor.googleauthorKwang Woong Lee-
dc.contributor.googleauthorJong Man Kim-
dc.contributor.googleauthorJae Geun Lee-
dc.contributor.googleauthorJe Ho Ryu-
dc.contributor.googleauthorDong Lak Choi-
dc.contributor.googleauthorHee Jung Wang-
dc.contributor.googleauthorBong Wan Kim-
dc.contributor.googleauthorDong Sik Kim-
dc.contributor.googleauthorYang Won Nah-
dc.contributor.googleauthorYoung Kyoung You-
dc.contributor.googleauthorKoo Jeong Kang-
dc.contributor.googleauthorHee Chul Yu-
dc.contributor.googleauthorYo Han Park-
dc.contributor.googleauthorKyung Jin Lee-
dc.contributor.googleauthorYun Kyu Kim-
dc.identifier.doi10.3346/jkms.2020.35.e36-
dc.contributor.localIdA00424-
dc.contributor.localIdA03068-
dc.relation.journalcodeJ01517-
dc.identifier.eissn1598-6357-
dc.identifier.pmid32056398-
dc.subject.keywordHepatitis B Virus-
dc.subject.keywordRecurrence-
dc.subject.keywordLiver Transplantation-
dc.subject.keywordHepatitis B Immunoglobulin-
dc.subject.keywordAntiviral Agent-
dc.contributor.alternativeNameKim, Myoung Soo-
dc.contributor.affiliatedAuthor김명수-
dc.contributor.affiliatedAuthor이재근-
dc.citation.volume35-
dc.citation.number6-
dc.citation.startPagee36-
dc.identifier.bibliographicCitationJOURNAL OF KOREAN MEDICAL SCIENCE, Vol.35(6) : e36, 2020-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.